The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of the safety and efficacy of INC280 in patients with advanced MET-dependent solid tumors.
Yung-Jue Bang
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Wu-Chou Su
No relevant relationships to disclose
Do-Hyun Nam
No relevant relationships to disclose
Wan-Teck Lim
Honoraria - Novartis
Todd Michael Bauer
No relevant relationships to disclose
Irene Brana
No relevant relationships to disclose
Ronnie Tung-Ping Poon
No relevant relationships to disclose
David S. Hong
Research Funding - miRNA Therapeutics
Chia-Chi Lin
No relevant relationships to disclose
Bin Peng
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Yingxi Zhang
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Sylvia Zhao
No relevant relationships to disclose
Arun Kumar
Employment or Leadership Position - Novartis
Mikhail Akimov
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Brigette Ma
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis